Selective α4β2 nAChR partial agonist (IC50 = 105 nM). Exhibits >20-fold selectivity for α4β2 over other nAChR subtypes. Increases dopamine turnover in rat nucleus accumbens in vivo. Orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 289.2. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.46 mL||17.29 mL||34.58 mL|
|5 mM||0.69 mL||3.46 mL||6.92 mL|
|10 mM||0.35 mL||1.73 mL||3.46 mL|
|50 mM||0.07 mL||0.35 mL||0.69 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Rollema et al (2010) Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br.J.Pharmacol. 160 334 PMID: 0331614
If you know of a relevant reference for Dianicline, please let us know.
View Related Products by Product Action
Keywords: nicotinic acetylcholine receptors nAChR partial agonists agonism selective α β alpha4beta2 orally bioavailable Nicotinic (a4b2) Receptors
Citations for Dianicline
Citations are publications that use Tocris products.
Currently there are no citations for Dianicline. Do you know of a great paper that uses Dianicline from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.